A non-interventional, 24-month prospective study of adult CD patients newly initiated on Ustekinumab as biologic therapy in Greece
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms REASSURE
- Sponsors Janssen-Cilag
Most Recent Events
- 04 Mar 2025 New trial record